NEW YORK, August 7, 2026, 18:00 EDT — U.S. markets closed.
Doximity NYSE:DOCS closed at $27.40, up 32.6% on Friday and roughly 31% for the week after fiscal first-quarter results.
The company raised its fiscal 2027 revenue outlook, but lowered its adjusted EBITDA outlook as it accelerates AI investment.
Management said no AI Search revenue was recognized in the first quarter, with most contracted AI Search revenue expected to begin in the third fiscal quarter.
Doximity stock — one month
Doximity NYSE:DOCS ended one of its strongest trading weeks in years after investors embraced its clinical AI strategy, even as management acknowledged that the new products have yet to contribute meaningful reported revenue. The shares closed at $27.40 on Friday, up 32.6% for the day and about 31% for the week.
The market’s reaction highlighted an unusual disconnect. Investors rewarded future AI monetization, while the latest guidance pointed to lower near-term profitability. That makes execution over the next two quarters far more important than the earnings beat itself.
The key investor question is simple. Can AI revenue arrive quickly enough to justify higher spending? Management said no AI Search revenue was recognized in the June quarter because deployments are still ramping, while most contracted AI Search revenue should begin arriving in the fiscal third quarter.
| Market reaction | Value |
|---|---|
| Friday close | $27.40 |
| Friday gain | +32.6% |
| Weekly gain | ~31% |
| Regular-session high | $40.00 |
| Close versus session high | -31.5% |
The first-quarter results were solid, although not flawless. Revenue exceeded Wall Street expectations, while adjusted earnings narrowly missed some published forecasts. Cash generation remained healthy.
| Fiscal Q1 2027 | Reported | Year earlier | Comment |
|---|---|---|---|
| Revenue | $156.6 million | $145.9 million | +7% year over year |
| Adjusted EBITDA | $74.8 million | $79.8 million | Lower year over year |
| Non-GAAP diluted EPS | $0.29 | $0.36 | Slightly below some analyst estimates |
| Free cash flow | $39.6 million | $60.1 million | Lower year over year |
Chief Executive Jeff Tangney said Doximity continues to see strong physician engagement across its AI products. Management also said AI Search query volume increased more than 25% sequentially, while AI Scribe users increased roughly tenfold from a year earlier.
Those usage metrics are encouraging. They have not yet translated into reported AI Search revenue. That gap explains why investors focused as much on guidance as on quarterly results.
| Fiscal 2027 outlook | Previous | Updated | Change |
|---|---|---|---|
| Revenue | $664M–$676M | $671M–$681M | Raised |
| Adjusted EBITDA | $323M–$335M | $309M–$329M | Lowered |
The updated outlook creates the article’s central investment debate. The revenue midpoint increased by only $6 million, while the adjusted EBITDA midpoint declined by $10 million. Investors are effectively paying today for earnings expected to arrive later, once AI products scale.
Wall Street generally welcomed the strategic direction, although opinions remain divided on valuation after Friday’s rally.
| Selected analyst recommendations | Recommendation | Latest target |
|---|---|---|
| Piper Sandler | Overweight | $47 |
| Needham & Company | Buy | $41 |
| Evercore | In Line | $40 |
| Raymond James Financial | Outperform | $38 |
| JPMorgan Chase | Neutral | $31 |
| BMO Capital Markets | Market Perform | $30 |
| Bank of America | Underperform | $20 |
Doximity also enters the second half with financial flexibility. The company remains debt-free, ended the quarter with a large cash and marketable securities position, and continues to repurchase shares.
Next week is unlikely to bring another company catalyst after earnings. Investors will instead watch for additional analyst revisions, while broader U.S. inflation and retail sales data may influence software valuations across the market.
Risks: Doximity’s AI strategy still depends on successful commercial rollout. Revenue guidance increased only modestly, while profitability guidance moved lower because of higher AI investment. If enterprise adoption or physician usage converts into revenue more slowly than management expects, investor enthusiasm could fade. Faster AI monetization or stronger healthcare marketing demand would represent the main upside risks.
